| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/AJCO.12834 |
| P698 | PubMed publication ID | 29243413 |
| P50 | author | Yuankai Shi | Q87711513 |
| P2093 | author name string | Xiaoyan Liu | |
| Sheng Yang | |||
| Jianping Xu | |||
| Xiangru Zhang | |||
| P2860 | cites work | Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters | Q24617999 |
| Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non-Small-Cell Lung Cancer: A Systematic Review | Q26801016 | ||
| Tumor angiogenesis: therapeutic implications | Q27860595 | ||
| Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo | Q29614729 | ||
| Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer | Q30422736 | ||
| VEGF receptor signaling in tumor angiogenesis | Q33914422 | ||
| CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer | Q34836398 | ||
| A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501. | Q36241287 | ||
| Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. | Q36345226 | ||
| World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. | Q36671054 | ||
| Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer | Q37424049 | ||
| Salvage treatment with apatinib for advanced non-small-cell lung cancer | Q37725637 | ||
| Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer | Q37877518 | ||
| Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lun | Q38382765 | ||
| Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience | Q38848914 | ||
| Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells | Q39418811 | ||
| Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction | Q39991776 | ||
| Cancer statistics in China, 2015. | Q40064386 | ||
| Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. | Q40483550 | ||
| Predictive imaging marker of bevacizumab efficacy: perfusion MRI. | Q42364159 | ||
| Efficacy and safety of bevacizumab-based therapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer in the phase III BO17704 study (AVAiL). | Q42846506 | ||
| Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment | Q43170414 | ||
| Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer | Q43299264 | ||
| A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805). | Q43943343 | ||
| Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab | Q48391705 | ||
| Brain Metastasis from Follicular Thyroid Carcinoma: Treatment with Sorafenib | Q48441783 | ||
| Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer | Q50941049 | ||
| BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer | Q51628000 | ||
| Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. | Q53507853 | ||
| Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer | Q54616228 | ||
| A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. | Q54621891 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 264-269 | |
| P577 | publication date | 2017-12-15 | |
| P1433 | published in | Asia Pacific Journal of Clinical Oncology | Q15757236 |
| P1476 | title | Clinical response to apatinib monotherapy in advanced non-small cell lung cancer | |
| P478 | volume | 14 |
| Q91725994 | A retrospective study of low-dose apatinib combined with S-1 in patients with advanced non-small cell lung cancer |
| Q90699038 | Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases |
| Q90352665 | Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study |
| Q58732685 | Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial |
| Q60961748 | Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy: A case report and literature review |
| Q64070319 | Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway |
| Q52583991 | Apatinib: A Review in Advanced Gastric Cancer and Other Advanced Cancers |
| Q91592081 | Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study |
| Q64963698 | Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: An observational study. |
| Q98664431 | Efficacy and safety of apatinib monotherapy in metastatic renal cell carcinoma (mRCC) patients: A single-arm observational study |
| Q64256900 | Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: A case report |
| Q90637341 | Therapeutic effect of small molecule targeting drug apatinib on gastric cancer and its role in prognosis and anti-infection mechanism |
Search more.